Document Detail


Alleviating effect of active hexose correlated compound (AHCC) for anticancer drug-induced side effects in non-tumor-bearing mice.
MedLine Citation:
PMID:  19827270     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Active hexose correlated compound (AHCC) is an extract of a basidiomycete mushroom that is used as a supplement by some cancer patients undergoing chemotherapy; it is thought to enhance the therapeutic effects and reduce the side effects of select anticarcinogenic agents. AHCC has been reported to strengthen the anticancer effects of cisplatin (CDDP) and ameliorate its side effects in female BALB/cA mice inoculated with Colon-26 tumor cells. In this study, the role of AHCC in alleviating the side effects induced by several other anticancer drugs was explored in non-tumor-bearing mice receiving monotherapy with paclitaxel (TAX), or multi-drug chemotherapy with TAX plus CDDP, 5-fluorouracil (5FU) plus irinotecan, CDDP plus 5FU, or doxorubicin plus cyclophosphamide. Outcomes from the drug treatment groups with and without AHCC supplementation were compared to controls that received vehicle alone. The multi-drug treatments significantly reduced bone marrow cell viability in all groups and leukocyte count in all groups except for TAX+CDDP; these myelosuppresive effects were generally alleviated by AHCC. Hepatotoxicity and nephrotoxicity caused by the treatments that included TAX and CDDP were also significantly improved by AHCC. The death rate was 20 to 30 percent in all treatment groups except TAX+CDDP, and supplementation with AHCC greatly reduced or eliminated mortality. These results support the concept that AHCC can be beneficial for cancer patients receiving chemotherapy.
Authors:
Kota Shigama; Akihiro Nakaya; Koji Wakame; Hiroshi Nishioka; Hajime Fujii
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of experimental therapeutics & oncology     Volume:  8     ISSN:  1359-4117     ISO Abbreviation:  J. Exp. Ther. Oncol.     Publication Date:  2009  
Date Detail:
Created Date:  2009-10-15     Completed Date:  2009-10-27     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9604933     Medline TA:  J Exp Ther Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  43-51     Citation Subset:  IM    
Affiliation:
Amino Up Chemical Co., Ltd., 363-32 Shin-ei, Kiyota, Sapporo 004-0839, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antineoplastic Agents / adverse effects*
Body Weight / drug effects
Bone Marrow / drug effects
Cisplatin / adverse effects
Female
Kidney / drug effects
Liver / drug effects
Male
Mice
Paclitaxel / adverse effects
Polysaccharides / pharmacology*
Chemical
Reg. No./Substance:
0/Active Hexose Correlated Compound; 0/Antineoplastic Agents; 0/Polysaccharides; 15663-27-1/Cisplatin; 33069-62-4/Paclitaxel

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Single fraction spine radiosurgery for myeloma epidural spinal cord compression.
Next Document:  Chimeric antigen receptors for stem cell based immunotherapy.